尿核基质蛋白22测定在膀胱癌诊断中的应用价值  

Evaluation of matrix protein 22 in the diagnosis of transitional cell carcinoma of bladder

作　　者：毕长富 张克荣 董浩 王丽艳 王占海 夏增学 

机构地区：[1]河北省秦皇岛市山海关人民医院外一科,066200

出　　处：《河北医药》2010年第14期1847-1848,共2页Hebei Medical Journal

基　　金：河北省科学技术研究与发展指导计划项目(编号:200901A126)

摘　　要：目的评价尿核基质蛋白22(NMP22)在膀胱移行细胞癌诊断中的意义。方法采用ELISA法测定57例膀胱癌疑似患者尿中NMP22水平以筛选膀胱癌,并与尿脱落细胞学检查进行比较。结果组织病理确诊膀胱癌38例。以10U/L为临界值,NMP22诊断膀胱移行上皮肿瘤的敏感性为81.6%,特异性为68.4%;尿脱落细胞学检查的敏感性为47.4%,特异性为89.5%。尿NMP22敏感性随肿瘤的分期、分级的升高而增加。结论尿NMP22检测比尿脱落细胞学检查更敏感,可以作为膀胱癌疑似患者的首选筛选方法。Objective To evaluate the significance of NMP22 as a marker for sereening transitional cell carcinoma in bladder. Methods The concentration of urinary NMP22 in 57 patients who were doubted with bladder cancer were detected by enzyme linked immunosorbent assay（ELISA） , and the results were compared with those detected by urinary eytology. Results 38 patients were diagnosed as bladder cancer by eystoseopy eombined with biopsy. Using 10 U/ml as threshold value, the overall sensitivity and specificity of urinary NMP22 assay were 81.6% and 68.4% respectively, and those of urinary eytology were 47.4% and 89. 5% respectively. The sensitivity of urinary NMP22 assay was correlated with the stage and grade of bladder cancer. Conclusion NMP22 is more sensitive but less specific than urinary cytology in detecting bladder cancer. It may serve as a first-line screening method for the patients with hematuria who are doubted with bladder cancer.

关 键 词：膀胱肿瘤 移行上皮细胞癌 核基质蛋白22 诊断 

分 类 号：R737.14[医药卫生—肿瘤]